透析不依从性与肾移植结局:一项回顾性队列研究
该回顾性队列研究链接美国国家透析治疗数据与移植登记数据,纳入2004至2014年接受维持性血液透析后行肾移植的9543例成人患者,评估5项透析不依从指标与移植后一年内移植物丢失、死亡和急性排斥的关联。结果显示高磷血症、大IDWG和缩短治疗与移植物丢失相关,大IDWG和缩短治疗与死亡相关,仅缩短治疗与急性排斥风险增加相关。作者认为行为学指标比实验室指标与结局关联更密切,在将不依从患者排除于移植等待名单前需谨慎考虑。
要点
- 高磷血症、大IDWG和缩短透析治疗与移植物丢失风险增加独立相关。
- 大IDWG和缩短治疗与移植后死亡风险增加相关,高钾和高磷则无此关联。
- 仅缩短治疗与急性排斥风险显著增加相关,行为学指标比实验室指标关联更强。
核心结论
- 透析不依从的合理指标与移植物及患者长期生存存在关联。
- 行为学指标(如缩短治疗、大IDWG)比实验室指标(如高钾、高磷)与移植结局关联更密切。
- 在将不依从行为作为排除透析患者进入移植等待名单的依据前,需仔细权衡其意义。
研究设计与样本
- 回顾性队列研究,链接美国国家透析治疗数据与移植登记数据。
- 纳入2004年1月1日至2014年12月31日接受维持性血液透析并在美国中心接受肾移植的成人患者,共9543例。
- 透析观察时间按3个月(季度)划分,计算每个季度各领域不依从测量次数。
- 采用Cox比例风险模型估计移植物丢失和死亡的HR,采用logistic回归估计排斥的OR。
主要发现
- 高磷血症(>5.5 mg/dL)与移植物丢失率升高相关(aHR 1.27,95%CI 1.08-1.49)。
- 大IDWG(≥5 L)与移植物丢失率升高相关(aHR 1.39,95%CI 1.23-1.59)。
- 缩短治疗(≥30 min)与移植物丢失率升高相关(aHR 1.54,95%CI 1.12-2.13),高钾血症(≥5.2 mEq/L)无显著关联。
- 大IDWG(aHR 1.49,95%CI 1.29-1.73)和缩短治疗(aHR 1.34,95%CI 1.13-1.58)与死亡相关,高钾和高磷无显著关联。
- 仅缩短治疗与急性排斥风险增加相关(aOR 3.88,95%CI 1.98-7.58);在2004-2009年限定模型中,漏治疗仅与死亡相关。
关键数值与推荐
- 高钾血症定义:血清钾≥5.2 mEq/L。
- 高磷血症定义:血清磷>5.5 mg/dL。
- 大IDWG定义:透析间期体重增长≥5 L。
- 缩短治疗定义:每次治疗缩短≥30 min。
- 漏治疗定义:≥1次 missed treatment(数据仅2004-2009年可用)。
临床怎么用
- 对透析等待名单患者评估不依从行为时,应关注缩短治疗和大IDWG等行为学指标。
- 不应仅凭高钾或高磷等实验室指标将患者排除于肾移植之外。
- 缩短治疗与急性排斥风险显著相关,移植前应针对性干预。
局限性
- 存在未测量的混杂因素(如饮食数据)。
- 所用的依从性指标可能具有多重、复杂的原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Concerns about nonadherent behaviors often prevent dialysis patients from entering waitlists for transplant even though there is an inconsistent association of these behaviors with posttransplant outcomes. We examined the association between plausible metrics of nonadherence related to dialysis treatment and posttransplant outcomes. STUDY DESIGN: Retrospective cohort. We linked national dialysis treatment data with transplant registry data. SETTING AND PARTICIPANTS: Adult patients receiving maintenance hemodialysis from January 1, 2004, through December 31, 2014, who received a kidney transplant at a US center. EXPOSURES: We examined 5 nonadherence metrics: serum potassium level (≥5.2 mEq/L), serum phosphorus level (>5.5 mg/dL), interdialytic weight gain (IDWG; ≥5 L), shortened treatments (≥30 min), and missed treatments (≥1); missed treatment data were available only for 2004-2009. These metrics were characterized per proportion of time under observation. Dialysis observation time was divided into 3-month intervals (quarters), and the number of nonadherent measurements in each domain was calculated for each quarter. OUTCOMES: Allograft loss, mortality, and acute rejection in the first posttransplant year. ANALYTICAL APPROACH: Using Cox proportional hazards and logistic regression, we estimated the hazard ratios for graft loss and mortality and odds ratios for rejection. RESULTS: 9,543 patients met inclusion criteria. In our primary model, hyperphosphatemia (adjusted hazard ratio [aHR], 1.27 [95% CI, 1.08-1.49]), large IDWG (aHR, 1.39 [95% CI, 1.23-1.59]), and shortened treatments (aHR, 1.54 [95% CI, 1.12-2.13]) were associated with greater rates of allograft loss, but hyperkalemia was not. Large IDWG (aHR, 1.49 [95% CI, 1.29-1.73]) and shortened treatments (aHR, 1.34 [95% CI, 1.13-1.58]) were associated with mortality, whereas hyperkalemia and hyperphosphatemia were not. Only shortened treatments were associated with an increased risk of acute rejection (adjusted odds ratio, 3.88 [95% CI, 1.98-7.58]). In models limited to the years 2004-2009 that included missed treatments, missed treatments were associated only with mortality. LIMITATIONS: Unmeasured confounding (eg, dietary data); adherence metrics used may have multiple, complex causes. CONCLUSIONS: Plausible measures of dialysis nonadherence have long-term associations with allograft and patient survival. Behavioral metrics were more closely associated with outcomes than laboratory markers were. The implications of nonadherent behaviors for dialysis patients must be carefully considered before patients are excluded from transplantation.
引用
- Sawinski D, Lindner H, Fitzsimmons R, et al. Dialysis Nonadherence and Kidney Transplant Outcomes: A Retrospective Cohort Study. Am J Kidney Dis. 2021. PMID: 34673160. doi:10.1053/j.ajkd.2021.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。